JP2010523497A - アデノシンａ２ａ受容体拮抗薬 - Google Patents

アデノシンａ２ａ受容体拮抗薬 Download PDF

Info

Publication number
JP2010523497A
JP2010523497A JP2010501235A JP2010501235A JP2010523497A JP 2010523497 A JP2010523497 A JP 2010523497A JP 2010501235 A JP2010501235 A JP 2010501235A JP 2010501235 A JP2010501235 A JP 2010501235A JP 2010523497 A JP2010523497 A JP 2010523497A
Authority
JP
Japan
Prior art keywords
pyrrolo
triazolo
furan
ethyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010501235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523497A5 (enExample
Inventor
アール モーマン アラン
Original Assignee
キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド filed Critical キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド
Publication of JP2010523497A publication Critical patent/JP2010523497A/ja
Publication of JP2010523497A5 publication Critical patent/JP2010523497A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2010501235A 2007-03-30 2008-03-28 アデノシンａ２ａ受容体拮抗薬 Withdrawn JP2010523497A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90910607P 2007-03-30 2007-03-30
US12/056,423 US7723343B2 (en) 2007-03-30 2008-03-27 Adenosine A2A receptor antagonists
US12/056,403 US7691869B2 (en) 2007-03-30 2008-03-27 Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
PCT/US2008/058544 WO2008121748A2 (en) 2007-03-30 2008-03-28 Adenosine a2a receptor antagonists

Publications (2)

Publication Number Publication Date
JP2010523497A true JP2010523497A (ja) 2010-07-15
JP2010523497A5 JP2010523497A5 (enExample) 2011-05-12

Family

ID=39795488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010501235A Withdrawn JP2010523497A (ja) 2007-03-30 2008-03-28 アデノシンａ２ａ受容体拮抗薬

Country Status (12)

Country Link
US (2) US7723343B2 (enExample)
EP (1) EP2129220A4 (enExample)
JP (1) JP2010523497A (enExample)
KR (1) KR20100014397A (enExample)
CN (1) CN101652067A (enExample)
AU (1) AU2008232690A1 (enExample)
BR (1) BRPI0808438A2 (enExample)
CA (1) CA2680075A1 (enExample)
IL (1) IL201234A0 (enExample)
MX (1) MX2009010223A (enExample)
NZ (1) NZ578720A (enExample)
WO (1) WO2008121748A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545721A (ja) * 2010-09-24 2013-12-26 アドヴィナス・セラピューティックス・リミテッド アデノシン受容体拮抗薬としての縮合三環化合物
JP2020512407A (ja) * 2017-03-30 2020-04-23 アイテオ セラピューティクス Ａ２ａ阻害剤及び癌の治療に使用するための化合物としての２−オキソ−チアゾール誘導体

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007263726A1 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
SI2299821T1 (sl) 2008-06-10 2016-03-31 Abbvie Inc. Triciklične spojine
JP2012510523A (ja) * 2008-12-03 2012-05-10 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ５ａの阻害剤
US8859566B2 (en) 2009-03-13 2014-10-14 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
PL2506716T3 (pl) * 2009-12-01 2017-10-31 Abbvie Inc Nowe związki tricykliczne
US8785639B2 (en) 2009-12-01 2014-07-22 Abbvie Inc. Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
WO2012149280A2 (en) * 2011-04-29 2012-11-01 Abbott Laboratories Novel tricyclic compounds
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
US20170129902A1 (en) 2015-10-16 2017-05-11 Abbvie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
JP7023933B2 (ja) * 2016-08-19 2022-02-22 ブリストル－マイヤーズ スクイブ カンパニー セコ－シクロプロパピロロインドール化合物、その抗体－薬物コンジュゲート、ならびに製造および使用方法
US11312719B2 (en) 2018-11-30 2022-04-26 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
AU7237294A (en) 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
MXPA02011625A (es) 2000-05-26 2003-03-27 Schering Corp Antagonistas receptores de adenosina a2a.
AR037243A1 (es) 2001-10-15 2004-11-03 Schering Corp Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
ATE453647T1 (de) 2001-11-30 2010-01-15 Schering Corp Adenosin a2a rezeptor antagonisten
HK1082662A1 (zh) 2002-05-30 2006-06-16 King Pharmaceuticals Research And Development Inc. 具有三环吡唑并三唑并嘧啶环结构的制药活性化合物及其使用方法
US20060128694A1 (en) 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
EP1622912B1 (en) 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
US7709492B2 (en) 2004-04-21 2010-05-04 Schering Corporation Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
CA2622741A1 (en) 2005-09-19 2007-03-29 Schering Corporation 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
AR056080A1 (es) 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545721A (ja) * 2010-09-24 2013-12-26 アドヴィナス・セラピューティックス・リミテッド アデノシン受容体拮抗薬としての縮合三環化合物
JP2020512407A (ja) * 2017-03-30 2020-04-23 アイテオ セラピューティクス Ａ２ａ阻害剤及び癌の治療に使用するための化合物としての２−オキソ−チアゾール誘導体
JP7197558B2 (ja) 2017-03-30 2022-12-27 アイテオ ベルギウム エスエー Ａ２ａ阻害剤及び癌の治療に使用するための化合物としての２－オキソ－チアゾール誘導体
JP2023027282A (ja) * 2017-03-30 2023-03-01 アイテオ ベルギウム エスエー Ａ２ａ阻害剤及び癌の治療に使用するための化合物としての２－オキソ－チアゾール誘導体

Also Published As

Publication number Publication date
BRPI0808438A2 (pt) 2014-07-29
NZ578720A (en) 2011-01-28
US7691869B2 (en) 2010-04-06
WO2008121748A3 (en) 2009-09-11
CN101652067A (zh) 2010-02-17
AU2008232690A1 (en) 2008-10-09
US7723343B2 (en) 2010-05-25
WO2008121748A2 (en) 2008-10-09
KR20100014397A (ko) 2010-02-10
EP2129220A4 (en) 2010-12-29
IL201234A0 (en) 2010-05-31
US20080242672A1 (en) 2008-10-02
US20080242673A1 (en) 2008-10-02
AU2008232690A2 (en) 2009-12-10
MX2009010223A (es) 2009-10-26
EP2129220A2 (en) 2009-12-09
CA2680075A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
JP2010523497A (ja) アデノシンａ２ａ受容体拮抗薬
JP4284181B2 (ja) アデノシンＡ２ａレセプターアンタゴニスト
CN100421663C (zh) 咪唑并（4,3－E）,1,2,4－三唑并（1,5－C）嘧啶类化合物作为腺苷A2a受体拮抗剂
JP4938348B2 (ja) アデノシンａ２ａレセプターアンタゴニスト
JP2025003975A (ja) ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
RU2632870C2 (ru) Трициклические гетероциклические соединения и ингибиторы jak
JP6585158B2 (ja) ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
JP4429724B2 (ja) ［１，２，４］−トリアゾール二環式アデノシンＡ２ａレセプタアンタゴニスト
JP2010526138A (ja) ピロロピリミジン−７−オン誘導体とその薬剤としての使用
JP2011529918A (ja) Ｊａｋ３阻害剤としてのピペリジン誘導体
JP2007535528A (ja) ヒスタミン−３受容体アンタゴニスト
US8785453B2 (en) Arylpiperazine-containing purine derivatives and uses thereof
HK1064100B (en) Adenosine a 2a receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110325

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110802